EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 10 (Octobre 2023) Med Sci (Paris), 39 10 (2023) 754-762 Références
Open Access
Numéro
Med Sci (Paris)
Volume 39, Numéro 10, Octobre 2023
Page(s) 754 - 762
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023125
Publié en ligne 9 novembre 2023
  1. Nicoletti A, Ainora ME, Cintoni M, et al. Dynamics of liver stiffness predicts complications in patients with HCV related cirrhosis treated with direct-acting antivirals. Digestive and Liver Disease 2023; may 2 :S1590–8658(23)00579–0. [Google Scholar]
  2. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 2016 ; 64 : S84–S101. [CrossRef] [PubMed] [Google Scholar]
  3. Costante F, Stella L, Santopaolo F, et al. Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection. J Hepatocell Carcinoma 2023; 10 : 713–24. [CrossRef] [Google Scholar]
  4. Diamond DL, Syder AJ, Jacobs JMet al. Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog 2010 ; 6 : e1000719. [CrossRef] [PubMed] [Google Scholar]
  5. Perrin-Cocon L, Kundlacz C, Jacquemin C, et al. Domain 2 of Hepatitis C Virus Protein NS5A Activates Glucokinase and Induces Lipogenesis in Hepatocytes. Int J Mol Sci 2022; 23 : 919. [CrossRef] [PubMed] [Google Scholar]
  6. Jung G-S, Jeon J-H, Choi Y-K, et al. Pyruvate dehydrogenase kinase regulates hepatitis C virus replication. Sci Rep 2016 ; 6 : 30846. [CrossRef] [PubMed] [Google Scholar]
  7. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 ; 126 : 840–848. [CrossRef] [PubMed] [Google Scholar]
  8. Hsieh M-J, Lan K-P, Liu H-Y, et al. Hepatitis C virus E2 protein involve in insulin resistance through an impairment of Akt/PKB and GSK3β signaling in hepatocytes. BMC Gastroenterol 2012 ; 12 : 74. [CrossRef] [PubMed] [Google Scholar]
  9. Wu Y-H, Yang Y, Chen C-H, et al. Aerobic glycolysis supports hepatitis B virus protein synthesis through interaction between viral surface antigen and pyruvate kinase isoform M2. PLoS Pathog 2021; 17 : e1008866. [CrossRef] [PubMed] [Google Scholar]
  10. Xie Q, Fan F, Wei W, et al. Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein in hepatocellular carcinoma cells. Sci Rep 2017 ; 7 : 41089. [CrossRef] [PubMed] [Google Scholar]
  11. Blanchard E, Roingeard P. The Hepatitis C Virus-Induced Membranous Web in Liver Tissue. Cells 2018 ; 7 : 191. [CrossRef] [PubMed] [Google Scholar]
  12. Andre P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002 ; 76 : 6919–6928. [CrossRef] [PubMed] [Google Scholar]
  13. Bartenschlager R, Penin F, Lohmann V, et al. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011 ; 19 : 95–103. [CrossRef] [PubMed] [Google Scholar]
  14. Scholtes C, Ramiere C, Rainteau D, et al. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology 2012 ; 56 : 39–48. [CrossRef] [PubMed] [Google Scholar]
  15. Piver E, Boyer A, Gaillard J, et al. Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture. Gut 2017 ; 66 : 1487–1495. [CrossRef] [Google Scholar]
  16. Yang W, Hood BL, Chadwick SL, et al. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology 2008 ; 48 : 1396–1403. [CrossRef] [PubMed] [Google Scholar]
  17. Hajjou M, Norel R, Carver R, et al. cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV. J Med Virol 2005 ; 77 : 57–65. [CrossRef] [PubMed] [Google Scholar]
  18. Wu Y-L, Peng X-E, Zhu Y-B, et al. Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein. J Virol 2016 ; 90 : 1729–1740. [CrossRef] [PubMed] [Google Scholar]
  19. Wang M-D, Wu H, Huang S, et al. HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress. Oncotarget 2016 ; 7 : 6711–6726. [CrossRef] [PubMed] [Google Scholar]
  20. Everts B, Amiel E, Huang SC, et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKepsilon supports the anabolic demands of dendritic cell activation. Nat Immunol 2014 ; 15 : 323–332. [CrossRef] [PubMed] [Google Scholar]
  21. Perrin-Cocon L, Aublin-Gex A, Sestito SE, et al. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci rep 2017 ; 7 : 40791. [CrossRef] [PubMed] [Google Scholar]
  22. Perrin-Cocon L, Aublin-Gex A, Diaz O, et al. Toll-like Receptor 4-Induced Glycolytic Burst in Human Monocyte-Derived Dendritic Cells Results from p38-Dependent Stabilization of HIF-1alpha and Increased Hexokinase II Expression. J Immunol 2018 ; 201 : 1510–1521. [CrossRef] [PubMed] [Google Scholar]
  23. Zhang Z, Trippler M, Real CI, et al. Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes. Hepatology 2020; 72 : 829–44. [CrossRef] [PubMed] [Google Scholar]
  24. Li Y-J, Zhu P, Liang Y, et al. Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells. World J Gastroenterol 2013 ; 19 : 2262–2269. [CrossRef] [PubMed] [Google Scholar]
  25. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007 ; 82 : 479–487. [CrossRef] [PubMed] [Google Scholar]
  26. Agaugue S, Perrin-Cocon L, andre P, et al. Hepatitis C lipo-Viro-particle from chronically infected patients interferes with TLR4 signaling in dendritic cell. PloS one 2007; 2 : e330. [Google Scholar]
  27. Zhang E, Ma Z, Li Q, et al. TLR2 Stimulation Increases Cellular Metabolism in CD8+ T Cells and Thereby Enhances CD8+ T Cell Activation, Function, and antiviral Activity. J Immunol 2019 ; 203 : 2872–2886. [CrossRef] [PubMed] [Google Scholar]
  28. Israelow B, Narbus CM, Sourisseau M, et al. HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology 2014 ; 60 : 1170–1179. [CrossRef] [PubMed] [Google Scholar]
  29. Zhang Z, Filzmayer C, Ni Y, et al. Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes. J Hepatol 2018 ; 69 : 25–35. [CrossRef] [PubMed] [Google Scholar]
  30. Fekete T, Sütö MI, Bencze D, et al. Human Plasmacytoid and Monocyte-Derived Dendritic Cells Display Distinct Metabolic Profile Upon RIG-I Activation. Front Immunol 2018 ; 9 : 3070. [CrossRef] [PubMed] [Google Scholar]
  31. Zhang W, Wang G, Xu ZG, et al. Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS. Cell 2019 ; 178 : 176–89.e15. [CrossRef] [PubMed] [Google Scholar]
  32. Zhou L, He R, Fang P, et al. Hepatitis B virus rigs the cellular metabolome to avoid innate immune recognition. Nat Commun 2021; 12 : 98. [CrossRef] [PubMed] [Google Scholar]
  33. Wei C, Ni C, Song T, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 2010 ; 185 : 1158–1168. [CrossRef] [PubMed] [Google Scholar]
  34. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005 ; 102 : 2992–2997. [CrossRef] [PubMed] [Google Scholar]
  35. Liu Y, Li J, Chen J, et al. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J Virol 2015 ; 89 : 2287–2300. [CrossRef] [PubMed] [Google Scholar]
  36. Ding Q, Cao X, Lu J, et al. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J Hepatol 2013 ; 59 : 52–58. [CrossRef] [PubMed] [Google Scholar]
  37. Pan Q, de Ruiter PE, Metselaar HJ, et al. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology 2012 ; 55 : 1673–1683. [CrossRef] [PubMed] [Google Scholar]
  38. Hoffmann H-H, Kunz A, Simon VA, et al. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 2011 ; 108 : 5777–5782. [CrossRef] [PubMed] [Google Scholar]
  39. Wang Y, Wang W, Xu L, et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. antimicrob Agents Chemother 2016 ; 60 : 2834–2848. [CrossRef] [PubMed] [Google Scholar]
  40. Ruan J, Sun S, Cheng X, et al. Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro. Virol J 2020; 17 : 89. [CrossRef] [PubMed] [Google Scholar]
  41. Hoppe-Seyler K, Sauer P, Lohrey C, et al. The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro. Hepatology 2012 ; 56 : 9–16. [CrossRef] [PubMed] [Google Scholar]
  42. Gong ZJ, De Meyer S, Clarysse C, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 1999 ; 6 : 229–236. [CrossRef] [PubMed] [Google Scholar]
  43. Ben-Ari Z, Zemel R, Tur-Kaspa R. The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance–no beneficial effect. Transplantation 2001 ; 71 : 154–156. [CrossRef] [PubMed] [Google Scholar]
  44. Verrier ER, Weiss A, Bach C, et al. Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets. Gut 2020; 69 : 158–67. [CrossRef] [PubMed] [Google Scholar]
  45. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012 ; 1 : e00049. [CrossRef] [PubMed] [Google Scholar]
  46. Mouzannar K, Fusil F, Lacombe B, et al. Farnesoid X receptor-alpha is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo. FASEB J 2019 ; 33 : 2472–2483. [CrossRef] [PubMed] [Google Scholar]
  47. Erken R, andre P, Roy E, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat 2021; 28 : 1690–8. [CrossRef] [PubMed] [Google Scholar]
  48. Legrand A-F, Lucifora J, Lacombe B, et al. Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity. Hepatol Commun 2023; 7 : e0078. [PubMed] [Google Scholar]
  49. Chiang JYL, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol 2022; 548 : 111618. [CrossRef] [PubMed] [Google Scholar]
  50. Song M, Sun Y, Tian J, et al. Silencing Retinoid X Receptor Alpha Expression Enhances Early-Stage Hepatitis B Virus Infection In Cell Cultures. J Virol 2018 ; 92 : e01771–e01717. [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.